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PancreasThe basic helix–loop–helix transcription factor Neurog3 (Neurogenin3 or Ngn3) actively drives endodermal
progenitor cells towards endocrine islet cell differentiation during embryogenesis. Here, we manipulate
Neurog3 expression levels in endocrine progenitor cells without altering its expression pattern using
heterozygosity and a hypomorph. Lowered Neurog3 gene dosage in the developing pancreatic epithelium
reduces the overall production of endocrine islet cells without signiﬁcantly affecting the proportions of
various islet cell types that do form. A reduced Neurog3 production level in the endocrine-directed
pancreatic progenitor population activates the expression of Neurog3 in an increased number of epithelial
progenitors. Yet a signiﬁcant number of these Neurog3+ cells detected in heterozygous and hypomorphic
pancreata, possibly those that express low levels of Neurog3, move on to adopt pancreatic ductal or acinar
fates. These data directly demonstrate that achieving high levels of Neurog3 expression is a critical step for
endocrine commitment from multipotent pancreatic progenitors. These ﬁndings also suggest that a high
level of Neurog3 expression could mediate lateral inhibition or other unknown feedback mechanisms to
regulate the number of cells that initiate Neurog3 transcription and protein production. The control of
Neurog3+ cell number and the Neurog3 threshold-dependent endocrine differentiation mechanism combine
to select a speciﬁc proportion of pancreatic progenitor cells to adopt the islet cell fate.
© 2009 Elsevier Inc. All rights reserved.Introduction
During early embryogenesis, the seemingly equivalent and likely
multipotent pancreatic precursors give rise to both exocrine (acinar
and ductal) or endocrine islet cells, in generally reproducible
proportions (Gu et al., 2002; Kawaguchi et al., 2002; Seymour et al.,
2007; Zhou et al., 2007). Neurog3 (Neurogenin3 or Ngn3) is essential
for endocrine differentiation. All endocrine islet cells are derived from
pancreatic progenitors that transiently express high levels of Neurog3
(Gu et al., 2002; Mellitzer et al., 2004; Schonhoff et al., 2004). Loss of
Neurog3 activity nearly abolishes endocrine islet cell differentiation
(Gradwohl et al., 2000; Wang et al., 2008). Conversely, ectopic
expression of Neurog3 results in precocious endocrine differentiation
from embryonic endodermal cells, with a differential stage-depen-
dent output of islet cell types (Apelqvist et al., 1999; Grapin-Botton et
al., 2001; Schwitzgebel et al., 2000). Remarkably, co-expression of
Neurog3 with MafA and Pdx1 converts adult acinar cells into β-like
islet cells (Zhou et al., 2008). Thus, understanding Neurog3 expression
and function is essential for elucidating islet cell neogenesis, and may).
ll rights reserved.be relevant for both in vitro differentiation of ES cells and in vivo
exocrine cell transdifferentiation, towards endocrine islets [(Yang and
Wright, 2009; Zaret, 2009) and references therein].
Previous studies have suggested that Neurog3+ cells are selected
by Notch-mediated lateral inhibition from a set of multipotent
pancreatic progenitor cells (MPCs) that maintain active Notch
signaling (Apelqvist et al., 1999; Jensen et al., 2000b). Speciﬁcally,
activated Notch converts transcriptional repressor RBP-J{kappa}/
CBF1 to an activator to up-regulate the expression of Hes (orthologs
of Hairy enhancer of split) or Hairy-related (Hey) genes (Fujikura et al.,
2006). Protein products of the Hes and Hey gene family members
directly repress Neurog3 transcription (Jensen et al., 2000b) to allow
for MPC maintenance. Stochastic events or asymmetries developed
during cell division cause a subset of MPCs to reduce the strength of
Notch signaling and raise Neurog3 level above a speciﬁc threshold
level for islet cell speciﬁcation and commitment (Apelqvist et al.,
1999; Jensen et al., 2000b).
Neurog3 directly activates the expression of several transcription
factor genes (Mellitzer et al., 2006; Petri et al., 2006; White et al.,
2008). Subsequently, these transcription factors cooperatively acti-
vate the expression of endocrine hormones and other necessary genes
that are involved in islet cell development and maturation (Artner
et al., 2007; Huang et al., 2000; Wang et al., 2007). During the
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express these transcription factors but not hormones have been
detected and are proposed to be different-staged endocrine progeni-
tors (Artner et al., 2007; Chiang and Melton, 2003; Jensen et al.,
2000a). Whether the level of Neurog3 expression or the activation of
any speciﬁc Neurog3 targets is the limiting step for producing mature
and functional islet cells remains unclear.
Other than activating the endocrine differentiation program,
Neurog3 was proposed to mediate lateral inhibition to properly
allocate the speciﬁc proportions of pancreatic MPCs to endocrine and
exocrine fates in a non-cell autonomous fashion (Skipper and Lewis,
2000). By analogy to studies of neuronal development (Kageyama
et al., 2008), it was proposed that Neurog3 upregulates the expression
of Notch ligand(s), raising nuclear Notch signaling in adjacent cells
non-cell-autonomously and preventing them from activating Neurog3
expression (Lewis, 1998; Meinhardt and Gierer, 1974). A result of
lateral inhibition is the preservation of mitotically active pancreatic
MPCs, which is critical for generating adequate endocrine mass
because most Neurog3 expressing cells are mitotically quiescent and
differentiated islet cells have limited proliferation capability (Gu et al.,
2002; Jensen et al., 2000a; Stanger et al., 2007). This model predicts
that the level of Neurog3 expression in individual pancreatic
progenitor cells is critical for controlling the proportion of progenitors
that activate Neurog3 expression.
Here, we demonstrate that a low level of Neurog3 expression in
individual pancreatic cells is not sufﬁcient to cause full differentiation
and end-stage endocrine hormone production. Consequently, a
portion of the Neurog3-expressing cells, possibly those expressing
low levels of Neurog3, adopts exocrine (both acinar and ductal) cell
fates. This ﬁnding suggests that pancreatic progenitor cells that turn
on a low level of Neurog3maintain a substantial degree of plasticity to
revert to exocrine progenitors: we propose that they are therefore
endocrine-biased and metastable. We further show that lowering
Neurog3 production activates Neurog3 in a larger proportion of
pancreatic progenitor cells, although the transcription levels of Notch
ligands in cells that express different levels of Neurog3 are not
signiﬁcantly altered. This latter ﬁnding suggests that Neurog3
mediates lateral inhibition with a Notch ligand transcription-
independent pathway(s) to control the abundance of Neurog3+ cells.
Materials and methods
Mouse strains and care
Mouse strain derivation/maintenance, crosses and treatments
follow protocols approved by the Vanderbilt Medical Center IACUC.
The noon of vaginal plug appearance was counted as embryonic day
0.5 (E0.5). Routine mouse embryo production utilized CD1 mice
(Charles River Laboratories, Inc. Wilmington, MA). The Neurog3F and
Neurog3− mouse strains were described previously (Wang et al.,
2008). Neurog3TgBAC-Cre; R26REYFP and Neurog3EGFP knockin mice were
generous gifts from A. Leiter (Schonhoff et al., 2004), F. Costantini
(Srinivas et al., 2001), and K. Kaestner (Lee et al., 2002), respectively.
Genotyping follows published methods with minor modiﬁcation.
Brieﬂy, tissue from an ear puncture was collected, boiled in 40 mM
NaOH for 30min. An equal volume of 0.1mMTris (pH: 5.0) was added
to neutralize. 1–3 μl of lysate was used in PCR genotyping.
Immunodetection
Immunoﬂuorescence (IF) and immunohistochemistry followed
established protocols. Tissues were prepared either as frozen or
parafﬁn sections. For frozen sections, dissected tissues were imme-
diately frozen in OCT and sectioned on the day of staining. Guinea pig
anti-glucagon, guinea pig anti-insulin, guinea pig anti-PP, and rabbit
anti-SS were fromDako, Carpinteria, CA. Rat anti-BrdU (BU1/75), goatanti-amylase, and rabbit anti-Ki67 were from ABCam, Cambridge, MA.
Mouse anti-mouse alpha tubulin and Dolichos Biﬂorus Agglutinin
(DBA) were from Sigma Aldrich, St Louis, MI. Secondary antibodies
used were: Cy3-conjugated donkey anti-rabbit IgG, Cy3-conjugated
donkey anti-mouse IgG, FITC-conjugated donkey anti-guinea pig IgG,
Cy3-conjugated donkey anti-goat, Cy5-conjugated donkey anti-
guinea pig IgG; and Cy5-conjugated donkey anti-rabbit (Jackson
Immunoresearch, West Grove, PA). All antibodies utilized 1:500–
1:2000 dilutions, depending on the amount of tissue on each slide.
Assays and quantiﬁcation
Intraperitoneal glucose tolerance test (IPGTT), serum insulin
assays, and insulin secretion from isolated islets were performed as
described (Wang et al., 2007). Western blot utilized α-tubulin as
loading control. 20 or 10 μg of total protein was loaded for each lane.
In order to assay islet mass, pancreata of each stage were weighted,
ﬁxed, and prepared as 6 μmparafﬁn sections. One of every 10 sections
was collected and stained with a mix of antibodies against insulin,
glucagon, PP, and SS, respectively, as HRP signals. Slides were counter-
stained with hematoxylin. Sections were then scanned by Ariol SL-50
(Genetix, Hampshire, UK) for quantitative IHC analysis to calculate
the ratio of the stained endocrine area over that of the total pancreas.
The islet mass was calculated based on the endocrine/exocrine ratio
and pancreas weight.
In order to examine the mitotic index of different pancreatic cells,
animals were injected IP with multiple doses of BrdU (at 50 mg/kg
body weight). For P1 animals, two doses at 2-h interval were
injected. For P10 animals, 4 doses at 2-h interval were injected.
Pancreata were then collected 2 h after the last BrdU injection.
Pancreata were then prepared as parafﬁn sections to assay for BrdU+
cells, which were visualized by IF and confocal imaging. Multiple
images/sections from each pancreas were counted to obtain
representative labeling indices.
Microscopy
Confocal microscopy (Zeiss LSM500) was utilized to visualize
ﬂuorescent images. Sampleswere processed side by side. Imageswere
captured using identical confocal parameters as Z-sections of one μm
thickness. Images were then projected onto a single plane for side-by-
side comparison for protein level/cell quantiﬁcation.
Fluorescence activated cell sorting and real time RT-PCR (QRTPCR)
E14.5 pancreata were dissected and genotyped. Batches of 8–10
individual EGFP+ pancreata were dissociated into single cells using a
mix of trypsin (0.05%) and Type IV collagenase (1 mg/ml). EGFP+
cells were collected using FACS. Before further analysis, a portion of
collected cells were spun onto glass slides utilizing Cytospin (Thermo
Shandon, Oak Park, MI) and examined for purity (by analyzing the
expression of hormones, and the presence of EGFP). The rest of the
samples were utilized for RT-PCR, with two duplicate cDNA prepara-
tions and four QRT-PCR (quantitative RT-PCR) reactions to assay the
mRNA levels. For each genotype, a minimum of three independent
batches of embryos was processed independently (i.e. the mRNA level
for each gene will be an average of 12 assays). Reverse-transcription
PCR (RT-PCR) follows standard protocol. cDNA synthesis and RT-PCR
were done by using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). QRT-PCR was performed using
mouse-speciﬁc primers (Table 1) with iQ SYBR Green Supermix on an
iCycler Thermal Cycler. The abundance of all transcripts was
normalized versus that of GAPDH. All statistical analyses utilized the
standard Student t-test. A P-value of b0.05 was considered signiﬁcant.
Quantiﬁcation data were presented as the mean±standard error of
the means.
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Reduced Neurog3 dosage impairs endocrine islet function
While analyzing the function of Neurog3 in differentiated
endocrine islet cells utilizing a conditional ﬂoxed Neurog3 allele
(Neurog3F), we noticed that Neurog3+/− and Neurog3F/−adult
animals displayed a signiﬁcantly compromised glucose-clearance
capacity over that of wild type littermates (+/+), suggesting
impaired pancreatic endocrine function (Wang et al., 2009). In the
Neurog3− allele, a CreERT open reading frame replaced 150 nucleo-
tides immediately downstream from the ATG start codon of endog-
enousNeurog3. Thus, this allele produces CreERT but not Neurog3, and
is expected to behave as a null allele. In the Neurog3Fallele, LoxP sites
ﬂank the Neurog3 coding region, with a CreERT cDNA lying farther 3′
(Wang et al., 2008). No DNA sequence was deleted around the
endogenous Neurog3 locus in the Neurog3F allele. Thus, we expect the
Neurog3 expression pattern (i.e. the speciﬁc cells that express
Neurog3) in Neurog3+/−and Neurog3F/− pancreata to be equivalent
to that of wild type littermates. Thus, the compromised endocrine
function in Neurog3+/−and Neurog3F/− animals over the wild type
littermates likely reﬂects some form of gene dosage or threshold effect
of Neurog3 on endocrine differentiation. We therefore systematically
examined how Neurog3 gene dosage affected islet cell differentiation
and function.
We obtained mice of different genotypes and assayed their
endocrine function with IPGTT assays at different ages. The fasting
blood glucose levels of the Neurog3+/+, Neurog3+/−, and Neurog3F/−
adultmice did not vary signiﬁcantly (Fig. 1A. Blood glucose levels at “0”
time point). Yet both male and female Neurog3+/− and Neurog3F/−
mice displayed signiﬁcantly compromised glucose-clearance capa-Fig. 1. Neurog3 dosage reduction impairs endocrine islet function. (A) IPGTT results of one an
2-month-old mice (both male and female mice included). The “Y” axis represents the ratio
insulin level before and 30 min after glucose challenge. Only male mice were utilized in C.bility at all ages tested, including 1 and 2 months after birth (Fig. 1A).
The Neurog3F/− mice showed a trend of lower glucose clearing
capability at 1 month of age than Neurog3+/− animals. This trend
became undetectable after 2 months of age (Fig. 1A). Despite being
glucose intolerant, the Neurog3+/− and Neurog3F/− animals do not
develop frank diabetes (ad lib-feeding blood glucose over 300 mg/dl)
even at 1 year of age (not shown).
In order to investigate whether the glucose-clearing defect in
Neurog3+/− and Neurog3F/− animals is due to either compromised
insulin secretion from β cells or reduced response of peripheral tissues
to insulin, we examined insulin sensitivity. Overnight fasted adult
mice were administered with insulin by intraperitoneal injection.
Their blood glucose level was assayed at different time points after the
insulin injection. All three groups of animals, when examined at
2 months of age, displayed similar proﬁles of blood glucose reduction
in response to insulin administration (Fig. 1B), demonstrating an
unaltered insulin sensitivity. Consistent with this insulin tolerance
result and the IPGTT defects above, the fasting serum insulin levels did
not vary signiﬁcantly between these three genotypes (Fig. 1C). Yet
30 min after glucose challenge, the Neurog3+/− and Neurog3F/−
animals showed signiﬁcantly reduced serum insulin up-regulation
compared with Neurog3+/+ control animals (Fig. 1C). Therefore,
Neurog3+/− and Neurog3F/− animals have compromised insulin
secretion in response to nutritional stimulation.
Neurog3 production is reduced in Neurog3+/− and Neurog3F/−
pancreata
We then determined the underlying mechanisms for the compro-
mised endocrine function in Neurog3+/− and Neurog3F/− animals.
We ﬁrst examined Neurog3 production in pancreata at severald 2-month-old animals (including both male and female mice). (B) Insulin sensitivity in
of glucose level at point of assay over glucose level prior to insulin injection. (C) Serum
⁎Pb0.05.
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immunoﬂuorescence (IF), western blot, and real time RT-PCR. For IF-
staining-based assays, pancreata of different genotypes were dissect-
ed and processed identically, side-by-side. After IF-staining, confocal
image series (as Z-sections of 1 micron thickness) were captured
under identical parameters and stacked as single images, so that the
ﬂuorescence of multiple nuclear focal planes was integrated to
estimate the total ﬂuorescence intensity within individual nuclei
(Materials and methods). The average Neurog3 levels in each
progenitor cell were visibly reduced in Neurog3+/− and Neurog3F/−
pancreata (Supplementary Fig. 1), as were the number of cells that
express high levels of Neurog3, with the caveat that this type of
nuclear abundance estimation is semi-quantitative (Fig. 2A). Yet
consistent with the IF-based assays, western blot analysis estimated
that the total amount of Neurog3 protein in Neurog3+/− and Neur-
og3F/− pancreata was signiﬁcantly reduced compared to Neurog3+/+
littermates (Fig. 2B), a result that is consistent with the abundance of
Neurog3 mRNA levels in Neurog3+/+, Neurog3+/−, and Neurog3F/−
pancreata (E15.5) (Fig. 2C). The lowered Neurog3F mRNA level could
be a result of its destabilization by the presence of a long 3′-UTR
(Amrani et al., 2006).
Reduced Neurog3 dosage decreases endocrine islet mass
We also investigated how the level of Neurog3 produced affects
endocrine function. In the adult pancreas, overall islet architecture didFig. 2. Neurog3 production is reduced in Neurog3+/− and Neurog3F/− pancreata. (A) IF (re
images captured at identical confocal parameters. White arrows, Neurog3HI cells. Green arrow
E15.5 pancreata. Each sample was loaded twice, with different amount of total protein load
visible bands under this condition. (C) Real time RT-PCR detection of Neurog3 mRNA leve
mRNA. ⁎Pb0.05.not vary among the various genotypes, with β cells mostly localized
within the islet core and α, δ, and PP cells localized peripherally (data
not shown). Signiﬁcantly, the average islet size and the abundance of
sectioned islets appeared reproducibly reduced in the order of WT,
Neurog3+/−, and Neurog3F/−(Fig. 3A–C). We estimated the total islet
mass by measuring islet area in several animals of various genotypes
in a subset of pancreatic sections (see Materials and methods). Total
islet mass was substantially reduced at P1 (postnatal day 1) and P28
in Neurog3+/− and Neurog3F/−animals than in Neurog3+/+ animals
(Fig. 3D).
In order to examine whether a reduction of Neurog3 expression
affects endocrine function of each islet cell after differentiation, we
examined the expression of several factors that are critical for
endocrine function after birth. We found that the hormone
expressing islet cells in all three groups of animals expressed similar
levels of Pdx1, Nkx6.1, Glut2, MafA, and MafB on per cell basis
(Supplementary Fig. 2). This ﬁnding suggests that the Neurog3 level
per cell does not appreciably affect endocrine differentiation,
provided that the Neurog3 level is high enough to allow endocrine
commitment (and differentiation) to be completed. In addition, we
tested the insulin secretion capability of islets isolated from 6-week-
old pancreata from the three groups of animals. To our surprise, the
straightforward Neurog3+/− heterozygous islets displayed a trend,
although statistically insigniﬁcant, of increased insulin secretion over
that of wild-type islets, in response to glucose stimulation. In
accordance with this trend, Neurog3F/− islets showed signiﬁcantlyd) detection of Neurog3 in pancreata at E14.5 and E16.5. Shown are projected Z-stack
s, Neurog3LO cells. Scale bars=20 μm. (B)Western blot detection of Neurog3 protein in
ed. α-tubulin was used as loading control. Note that Neurog3 protein migrated as two
ls in E15.5 pancreata. Presented are relative mRNA levels normalized against amylase
Fig. 3. Reduced Neurog3 production decreases pancreatic islet cell production. (A–C) Representative images of islets in 4-week-old pancreata in different genotyped animals. Islets
were visualized as brown cell clusters by HRP-based IHC assays against a combination of insulin, glucagon, SS and PP antibodies. Scale bar=50 μm. (D) Quantiﬁcation of islet mass at
1 day (P1) and 4 weeks after birth (P28). The islet masses in wild type animals were artiﬁcially set at 100%. (E) Insulin secretion in isolated islets of 2-month-old male mice. The
X-axis represents the % of total insulin in isolated islets that is released within 1 h under 20 mM glucose stimulation. ⁎Pb0.05.
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This observation could explain why Neurog3F/−animals, which have
reduced islet mass compared with Neurog3+/−animals, have
statistically similar IPGTT proﬁles to their Neurog3+/− littermates.
It is not clear at present what causes the enhanced insulin secretion
in islets isolated from Neurog3F/−animals. It could represent an
unknown aspect of improper differentiation. Alternatively, it could
represent an adaptive behavior of the islets, which up-regulate
glucose-induced insulin secretion to compensate for insulin insufﬁ-
ciency. Such a process is known to occur prior to phenotypic
manifestation of Type II Diabetes in human patients (Prentki and
Nolan, 2006).
The Neurog3 expression level does not affect pancreatic cell proliferation
In order to examine whether a reduced Neurog3 production
compromises pancreatic cell proliferation, we assayed pancreatic
weight and cell division at various stages. At P1, P10, and P16, the
pancreatic mass normalized to body weight remains unchanged in
wild type, Neurog3+/−, and Neurog3F/− animals (Supplementary
Fig. 3). We assayed both the mitotic indices with BrdU incorporation
in the exocrine (ducts, acini) and the four major endocrine cell types
(α, β, δ, and PP). At E17.5 and P10, two representative stages when
pancreatic cells are actively dividing, the mitotic indices of these
speciﬁc pancreatic cells in wild type, Neurog3+/−, and Neurog3F/−
pancreata were similar (Fig. 4 and Supplementary Fig. 4). Thesecombined data suggest that Neurog3 dosage does not affect cell
division and that the observed endocrine mass reduction in
Neurog3+/− and Neurog3F/− animals are likely caused by reduced
neogenesis (i.e. direct differentiation of Neurog3+ progenitors to
form islet endocrine cells) during embryogenesis, rather than
compromised cell proliferation during fetal or postnatal animal
growth. Along this line, we examined whether the fate or number
of Neurog3+ cells was altered when Neurog3 dosage was reduced.
Lowered Neurog3 dosage shunts Neurog3+ cells to an exocrine cell fate
Neurog3CreERT transgene or knock-in mouse-based lineage studies
with the Z/AP reporter line (Lobe et al., 1999) have shown that
most, if not all, pancreatic progenitors that express a high level of
Neurog3 will adopt an endocrine islet cell fate (Gu et al., 2002;
Johansson et al., 2007). Neurog3TGBAC-Cre transgenic-BAC-based
studies suggest that a low but signiﬁcant fraction of pancreatic
progenitors that express Neurog3, detected with the more sensitive
Cre reporter R26R, gives rise to exocrine cells (Schonhoff et al., 2004;
CW, unpublished observations). Based on these latter ﬁndings, we
hypothesized that the level of Neurog3 is critical for moving
pancreatic progenitors to an endocrine-biased condition. We tested
to see if lowering Neurog3 expression level in individual cells would
allow more Neurog3+ cells to divert to an exocrine fate. This
possibility could explain why endocrine islet cell production is
reduced in Neurog3+/− and NeurogF/− animals.
Fig. 4. Pancreatic cell division is not affected by Neurog3 dosage reduction. (A–C) Representative images of BrdU labeling in E17.5 pancreata. (D–F) BrdU labeling in P10 pancreata.
DAPI was used to visualize nuclei and insulin signals mark β cells. Scale bar=20 μm. (G and H) Mitotic indices in E17.5 and P10 pancreata. The indices in β cells and exocrine cells
(including both duct and acinar cells) are presented separately.
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mice to trace the fate of Neurog3+ cells in both wild type and
heterozygous backgrounds. The advantage of this binary-switch
approach is that we can detect all cells that express Neurog3 at a
level above the threshold for Cre activity, because the activation of
R26REYFP leads to a similarly strong level of EYFP, irrespective of cell
fate, and therefore their unambiguous detection.
The lineage of Neurog3+ progenitor cells was monitored at
embryonic and newborn stages. In the E14.5 Neurog3TGBAC-Cre;
R26REYFP wild-type pancreas, most EYFP+ cells appeared as clusters
of endocrine cells (Fig. 5A1-A2), with only occasional EYFP+ cells
localized in duct (Fig. 5A3) or acinar cells (Fig. 5A4). By contrast, in the
E14.5 Neurog3+/−; Neurog3TGBAC-Cre; R26REYFP pancreas, a substantial
number of EYFP+ cells appeared in exocrine acinar and ductal cells
(Fig. 5B). The similar EYFP+ cell distribution between endocrine and
exocrine tissues was observed at newborn and P10 (data not shown):
that is, more exocrine cells express EYFP in Neurog3+/− pancreas, and
are thus derived from Neurog3-expressing progenitors. Quantitative-
ly, while about 15% of Neurog3TGBAC-Cre-labeled cells were found to
express exocrine cell markers in the wild-type background, about 45%
of the labeled cells were found within the exocrine lineage in the
heterozygous Neurog3+/− pancreas: more Neurog3+ precursors
adopt an exocrine fate with Neurog3 dosage reduction (Fig. 5D).These data strongly suggest that Neurog3 expression must reach a
threshold (“high”) level in order to trigger the commitment of
progeny towards endocrine differentiation. At lower Neurog3 levels,
many more progeny of Neurog3-expressing cells maintain multi-
potent-progenitor-like activity and can “reallocate” to the exocrine
acini or duct fates. Consistent with this hypothesis, total inactiva-
tion of Neurog3 did not eliminate the presence of cells that
activated the Neurog3 promoter. Instead, the cells that activated
the Neurog3 promoter (and therefore also induced to express Cre
from Neurog3TgBAC-Cre) were relocated to the exocrine tissues,
including exocrine acinar and pancreatic ducts (Fig. 5C).
We also examined the fate of Neurog3+ cells in the Neurog3F/−
compound heterozygous animals (hypomorphic ﬂoxed allele over
null) using the Neurog3TgBAC-Cre-based lineage tracing. Neurog3F/−;
Neurog3TgBAC-Cre; R26REYFP animals were derived. In these mice,
Neurog3 was immediately inactivated when its own transcription
was activated. As a result, the Neurog3F/−; Neurog3TgBAC-Cre; R26REYFP
pancreata contained nearly no endocrine cells and most of the EYFP-
expressing cells were located in the exocrine tissue (not shown).
However, these data were difﬁcult to interpret, since we do not
know the time frame during which Neurog3TgBAC-Cre inactivates the
Neurog3F allele. We therefore did not further investigate the
phenotype in Neurog3F/−; Neurog3TgBAC-Cre; R26REYFP animals.
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pancreatic progenitors
We counted the total number of pancreatic cells derived from
Neurog3+ progenitors (i.e. the cells that activated the R26REYFP
reporter) at P1. The total number of EYFP+ pancreatic cells (acinar,
duct, and islet cells) was signiﬁcantly increased in Neurog3+/−
pancreata over that in wild-type animals (from 4% to 8% of the totalFig. 5. Lowered Neurog3 activity shunts more Neurog3+ cells to exocrine fate. (A1, B1, and C1
genetic background. Shown are whole mount pictures. Dotted lines circle the pancreata. (A2–
or C showed images from one individual pancreas, respectively. Panels labeled with 2, 3, and
mix of all hormones). Scale bars=50 μm. (D) % of EYFP+ cells that are of islet, acinar, andpancreatic cells with no variation of total pancreatic mass. Supple-
mentary Fig. 5). At least three sources could account for this increase
in cells activating Neurog3 expression. First, Neurog3 could be
ectopically activated in differentiated acinar cells. Because we could
not detect Neurog3 expression in exocrine acinar cells with immuno-
detection or Neurog3EGFP reporter expression (Fig. 6 and data not
shown), this possibility is unlikely to occur. Second, if more Neurog3+
progenitors were allocated into exocrine (acinar and duct) pancreas) EYFP expression (white) in E14.5 Neurog3TgBAC-Cre; R26REYFP pancreata under different
C4) IF showing the identities of EYFP+ pancreatic cells (E14.5). Panels markedwith A, B,
4 showed the identity of EYFP+ cells with different antibodies (Amy: amylase; Horm:
duct cells (n=6). Neonatal tissues were used in D.
Fig. 6.More pancreatic progenitor cells activate Neurog3 expression with reduced Neurog3 dosage at E14.5. (A and B) Immuno-characterization of EGFP+ cells in Neurog3EGFP/+ and
Neurog3EGFP/F pancreata and sorted cells. DAPI was used to mark nuclei. (A1 and B1) Expression analysis of unsorted pancreatic cells. Note the large number of EGFP+ cells (green)
and amylase (blue) or hormone expressing (red) cells. (A2, A3, B2, and B3) Characterization of sorted EGFP+ cells. Note that the sorted cells do not express amylase and only few
EGFP+ cells express hormone (white arrow in A3). A4 and B4 show the same views as A3 and B3, respectively, yet with only the green channel shown. (C) Average number of EGFP+
cells in Neurog3EGFP/+ and Neurog3EGFP/F pancreata. (D) Ki67 expression in Neurog3EGFP/+ and Neurog3EGFP/F pancreata. Note the lack of Ki67 signal in endocrine progenitor cells
(that express Neurog3, green) or endocrine cells (that express hormones, blue) at this stage. Scale bar=40 μm.
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tomore EYFP+ descendents. This possibility is known to play a role for
the increased EYFP+ pancreatic cells in Neurog3+/− mice because
acinar cells divide twice as frequently as endocrine islet cells (Fig. 4
and supplementary Fig. 4). However, the fact that more Neurog3+
cells were allocated to the exocrine progenitor pool also suggests the
third possibility: more pancreatic progenitors might have activated
Neurog3 expression when its gene dosage was reduced, because
reduced number of Neurog3HI cells had likely weakened Neurog3-
mediated lateral inhibition. In order to examine this third possibility,
we directly examined the number of Neurog3+ cells in the embryonic
pancreas.
The number of Neurog3+ cells was counted utilizing the
Neurog3EGFP knockin mice (Lee et al., 2002). In this allele, EGFP
replaces the endogenous Neurog3 coding sequence. The selection of
this line instead of the Neurog3EGFP-tg line (a transgenic line with a
relatively short promoter region; Gu et al., 2004) was made to try to
ensure that EGFP production recapitulates that of the endogenous
Neurog3 gene. The limitation is that we could not assay the number
of Neurog3+ cells in the wild-type background. Yet this deﬁciency didnot prevent us from examining the basic principle of whether or not a
reduced Neurog3 gene function would result in an increase in the
number of Neurog3+ cells. We did not utilize antibodies to directly
assay the number of Neurog3+ cells, because of the inherent problem
of immunostaining in deﬁning the signal-to-background ratios
between different samples, especially when the gene expression
levels are low (See Supplementary Fig. 1 for an example).
At E14.5, when large numbers of endocrine progenitor cells
appeared and exocrine differentiation started to occur, Neurog3EGFP/+
and Neurog3EGFP/F pancreatic buds were isolated and dissociated into
single cells. The samples were subjected to analysis by ﬂuorescence-
activated cell sorting, which counted and simultaneously puriﬁed the
EGFP+ cells. Collected cellswere spun onto slides for purity assays. Over
97% of the FACS-sorted cells emitted detectable green ﬂuorescence
(with 1000–2000 cells counted for each sample. Figs. 6A and B). We
could not detect any amylase+ cells in the sorted samples. Only
occasionally could we detect cells that express endocrine hormones
(Figs. 6A3 and B3). Indeed, we found that the number of Neurog3+ cells
was substantially greater in the Neurog3EGFP/Fthan in the Neurog3EGFP/+
animals (Fig. 6C).
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have a higher division rate in Neurog3EGFP/+ than in Neurog3EGFP/F
pancreata. Ki67, which is expressed in all stages of cell cycles of
proliferating cells, was chosen to examine the proliferation status of
Neurog3+ cells at E13.5, E14.5, and E15.5, which are the three stages
when large numbers of Neurog3+ cells were produced. We again
utilized EGFP production in both Neurog3EGFP/+ and Neurog3EGFP/F
animals as a surrogate for Neurog3 in order to avoid artiﬁcially
deﬁning an immunodetection Neurog3 signal. As reported in wild-
type Neurog3+ cells (Jensen et al., 2000a), most of the EGFP+ cells in
the Neurog3EGFP/+ and Neurog3EGFP/F pancreata did not express Ki67
(Fig. 6D and data not shown). These ﬁndings suggest that the
increased number of Neurog3+ cells in Neurog3EGFP/Fthan in the
Neurog3EGFP/+ pancreas results from increasing the numbers of
pancreatic progenitors that activate Neurog3 expression, rather than
from an increased mitotic division of the Neurog3+ cells.
Reducing Neurog3 activity does not reduce Notch ligand expression at a
global level
Overall, the ﬁndings above demonstrate that the Neurog3 protein
level within speciﬁc cells can feed back to the epithelium to regulate
the production of Neurog3+ cells, which is consistent with the
hypothesis that Neurog3 expression is linked to a lateral inhibition
process (Skipper and Lewis, 2000). In the classical Notch-based lateral
inhibition model, down-regulation of nuclear Notch activity lowers
the Hes/Hey expression that is responsible for activating the cell-
autonomous proneural gene expression (which is the pro-endocrine
gene Neurog3 in endocrine pancreatic development). One function of
the proneural gene is to raise the expression of Notch ligands, Delta or
Jagged, which consequently potentiate Notch activity in neighboring
progenitors, and repress expression of proneural genes in these
neighbors. Because our above ﬁnding is consistent with Neurog3
normally being intimately linked to lateral inhibition, such that its
expression is prevented from spreading to neighboring cells, we
tested for evidence of which Notch ligand was utilized.
We again utilized the knockin mouse line, Neurog3EGFP, to
isolate EGFP+ cells in both the Neurog3EGFP/+ (heterozygous) and
Neurog3EGFP/F (Hypomorphic) backgrounds. Since we expect the
Notch pathway to operate via a similar mechanism in Neurog3+/+,Fig. 7. Neurog3LO progenitor cells have a higher Notch activity but not-reduced Notch lig
components and pancreatic progenitor markers in Neurog3EGFP+ cells. ⁎Pb0.05.Neurog3EGFP/+, or Neurog3EGFP/F cells, we omit wild-type Neurog3+
cells (which are untagged and therefore not sortable) for this analysis,
which, in principle, should not affect our data interpretation.
EGFP+ cells were ﬂow-cytometrically isolated from E14.5
embryonic Neurog3EGFP/+ and Neurog3EGFP/F pancreata to over 95%
purity. QRT-PCR analysis of several well-established Notch compo-
nents was carried out [(Fig. 7). Hes3, Hes5, Notch2, and Notch3
expression levels were below the detection limits and were not
investigated in detail]. As expected, lowered Neurog3 production in
the Neurog3EGFP/Fpancreas resulted in higher Notch activity, that is,
EGFP+ cells from Neurog3EGFP/Fpancreata had higher levels of Hes1,
Hey1, and Notch1 expression than EGFP+ cells from Neurog3EGFP/+
pancreata (Fig. 7). The expression of Hes6, although detected at high
levels in EGFP+ cells, did not vary between Neurog3EGFP/+ and
Neurog3EGFP/Fpancreata (Fig. 7). Consistent with a recent report that
Mfng expression depends on Neurog3 activity (Golson et al., 2009;
Svensson et al., 2009), its expression was signiﬁcantly reduced in
Neurog3EGFP/Fpancreata from that in Neurog3EGFP/+cells. Surprisingly,
the EGFP+ cells from the Neurog3EGFP/+and Neurog3EGFP/F pancreata
produced similar levels of mRNA for Delta1, Delta3, Delta4, and
Jagged2. Contrary to our prediction, the expression of another Notch
ligand, Jagged1, was signiﬁcantly increased with lowered Neurog3
dosage. These somewhat confounding results suggest, but do not
prove, that Neurog3 does not utilize increases in the classical Notch
ligand, at the transcription level, to mediate lateral inhibition in
pancreatic progenitors.
We also assayed the expression of several pancreatic progenitor
markers, including Ptf1a (Kawaguchi et al., 2002), Mist1 (Pin et al.,
2001), and Sox9 (Seymour et al., 2007). We found that both Ptf1a and
Mist1mRNAs were detected at low levels in sorted EGFP+ cells. Their
expression levels did not vary in the Neurog3+ cells of Neurog3EGFP/+
and Neurog3EGFP/F pancreata. This ﬁnding suggests that the reduction
of Neurog3 dosage does not directly activate the exocrine differenti-
ation or repress the pancreatic progenitor program in Neurog3+ cells.
In contrast, the Neurog3+ cells in Neurog3EGFP/F animals had a14-fold
increase of Sox9 mRNA than those in the Neurog3EGFP/+ animals. This
ﬁnding suggests that either the Sox9+ progenitors activate Neurog3
expression prematurely or that the Neurog3+ cells maintain
Sox9 expression more highly in Neurog3EGFP/F pancreata than in
Neurog3EGFP/+ pancreata.and transcription. QRT-PCR assay of mRNA levels for several well established Notch
Fig. 8. A model on Neurog3 expression level and pancreatic cell differentiation. (A)
Pancreatic progenitors do not express detectable levels of Neurog3. Stochastic events or
other processes activate low Neurog3 expression to start a possible journey towards
endocrine differentiation. Neurog3LO cells could go on to become Neurog3HI cells, under
the direction of unknown molecules, and differentiate into endocrine islet cells. A
portion of Neurog3LO cells could also revert to Neurog3− (OFF) progenitor status or
directly adopt exocrine cell fate. (B) Compensatory islet cell production with limited
Neurog3 expression reduction. In wild type pancreas, most Neurog3+ cells produce
high enough Neurog3 activity to allow for endocrine differentiation. In Neurog3+/−
pancreas, the average level of Neuog3 is lowered. However, a weakened lateral
inhibition increases the number of progenitor cells that express a medium-high level of
Neurog3, which partially compensates for the loss of progenitors that express a very
high level of Neurog3.
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Endocrine islet cells have a limited capacity to divide under normal
physiological conditions, and this process may be restricted further by
isotype-speciﬁc proliferation [e.g., beta cells only producing beta cells
(Herrera, 2000; Dor et al., 2004)]. Therefore, islet mass in individual
animals is predominantly determined by the controlled allocation of
pancreatic progenitors to the endocrine lineage during organogenesis
(Stanger et al., 2007). While it is known that activation of Neurog3 in
pancreatic progenitors is essential for cells to adopt the endocrine
fate, it remains unclear how only a speciﬁc portion of pancreatic
progenitors activates Neurog3 expression, or how the Neurog3 level
within each cell affects endocrine differentiation. Here, we show that
the high level of Neurog3 expression within individual progenitor
cells is critical for the allocation of pancreatic progenitor cells towards
the endocrine cell lineage. We further show that although reduced
Neurog3 expression causes more pancreatic progenitors to activate
low levels of Neurog3 expression (Neurog3LO), most of these
Neurog3LO cells are incapable of becoming endocrine cells, and
many move to exocrine fates. Thus, a reduction in Neurog3 dosage
results in a net reduction of endocrine differentiation.
High Neurog3 activity drives endocrine commitment
Examination of Neurog3 expression at various stages of pancreas
organogenesis detects cells with low (Neurog3LO) or high (Neurog3HI)
levels ofNeurog3 (Apelqvist et al., 1999; Gradwohl et al., 2000; Gu et al.,
2002; Schwitzgebel et al., 2000; Villasenor et al., 2008) (D. Boyer and
CW, submitted). It is possible that the Neurog3LO and Neurog3HI cells
represent different time-points in a process whereby equivalent
progenitor cells move relatively rapidly from Neurog3− (progenitor
status) to Neurog3LO, up to Neurog3HI then back to Neurog3LO/
Neurog3− (these cells now having adopted a committed-endocrine-
status) (Fig. 8A). In this case, all Neurog3+ cells would be expected to
reach identical fates. Alternatively, some Neurog3LO progenitor cells
may “back-up” or become diverted (even quite directly) into the
exocrine fate, or theymight die. Direct lineage tracing has begun to shed
light on these twopossibilities.When a CreERT-based lineage studywas
performed in NeurogCreERT knock-in animals, most, if not all, CreERT-
expressing cells give rise to endocrine islet cells (Johansson et al., 2007).
Because the limited CreERT cell-labeling efﬁciency only allowed for the
marking of Neurog3HI cells, this observation demonstrated that most, if
not all, Neurog3HI cells move forward into the endocrine program.
Conversely,Neurog3TgBAC-Cre-based lineage tracing showed that, even in
the wild-type situation, a portion of Neurog3-expressing precursors
gives rise to exocrine cells (Schonhoff et al., 2004). These combined
ﬁndings lead to the hypothesis that the Neurog3LO progenitor cells
maintain some degree of plasticity towards exocrine fates.
Our ﬁndings here demonstrate that, indeed, Neurog3 activity must
reach a high level for endocrine differentiation to occur. Most Neurog3LO
cells, if they fail to activate high Neurog3 expression, adopt exocrine
(acinar or ductal) cell fates. Therefore, pancreatic progenitors maintain
their multipotency, i.e. the ability of a group of cells to give rise to
multiple cell types, until their respective Neurog3 expression reaches a
speciﬁc level. In otherwords, pancreatic progenitors are not pre-selected
to become endocrine progenitors before Neurog3 activation. This
Neurog3 level “check point” provides pancreatic MPCs with some
tolerance to theﬂuctuationof endocrine-inducing signals: if low levels of
Neurog3were to be induced inmost pancreatic progenitors either due to
stochastic events, gene expression ﬂuctuation, or even in the presence of
certain genemutations, progenitors would not be forced to differentiate
into endocrine islet cells. This mechanism would provide a way to
prevent premature pancreatic MPCs exhaustion because of improper
endocrine differentiation.
Why a low level of Neurog3 expression is not sufﬁcient to
activate the endocrine differentiation program, or repress exocrinedifferentiation, is not clear. It is likely that the various Neurog3
target genes possess different Neurog3 recognition sequences or
combinations of different motifs with different afﬁnities to Neurog3.
As a result, high levels of Neurog3 are required to activate a set of
targets, which are all necessary for endocrine differentiation. At low
levels, Neurog3 might activate only some of its targets, a situation
insufﬁcient to commit and move from the progenitor state. Our
recent ﬁnding of Neurog3 function in differentiated β cells is
consistent with this type of speculation (Wang et al., 2009). In
that study, we found that differentiated islet cells maintain a low yet
detectable level of Neurog3 expression. We further showed that a
selective deletion of Neurog3 in newly born or mature adult β cells
compromised the expression of several, but not all, known Neurog3
targets (Wang et al., 2009). This observed Neurog3 requirement for
endocrine gene expression in differentiated islet cells does not
appear to be a consequence of compromised endocrine differenti-
ation in Neurog3F/− animals. As we have shown here, the β cells of
the Neurog3F/− pancreas have enhanced insulin secretion in
response to glucose stimulation. Nevertheless, whether different
levels of Neurog3 activate the expression of different endocrine gene
sets could only be directly examined with the future availability of
high afﬁnity/speciﬁcity Neurog3 antibodies.
Neurog3 mediates lateral inhibition or unknown mechanisms to regulate
the number of Neurog3 expressing cells
Reduced Neurog3 dosage results in Neurog3 expression in more
pancreatic progenitors, demonstrating the reverse correlation be-
tween the Neurog3 level per cell and the number of Neurog3+ cells in
the developing pancreas. This type of feedback mechanism likely
promotes the production of adequate number of endocrine islet cells.
To this end, Neurog3+/− pancreas tends to produce less Neurog3HI
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pancreatic epithelial cells to activate Neurog3 expression. As a result,
these “extra” Neurog3+ (most likely expressing a ‘medium level’ of
Neurog3) will partially compensate for the loss of some progenitors
that would have normally expressed the highest levels of Neurog3 to
adopt endocrine islet cell fate (Fig. 8B).
Surprisingly, a lowered Neurog3 activity does not signiﬁcantly
reduce the transcription levels of any Notch ligand that has been
tested, a ﬁnding seemed to contradict the hypothesis that Neurog3
normally up-regulates Notch ligand expression to mediate the
classical lateral inhibition (Skipper and Lewis, 2000). It is possible
that the real time RT-PCR assays are not sensitive enough to detect a
small reduction in the transcription of individual Notch ligands (e. g.,
Delta1 in Fig. 7). Alternatively, Neurog3 could utilize post-transcrip-
tional mechanism to regulate Notch activity. For example, Neurog3
could regulate the sub-cellular localization of Notch ligands. It is also
possible Neurog3 could modulate Notch activity through modiﬁers
such as Mfng (whose expression is reduced when Neurog3 expression
level is reduced), as demonstrated by biochemical analysis (Panin
et al., 2002). Lastly, it is also possible that the classical lateral
inhibition does not apply in the Notch-Ngn3 pathway. Instead, the
altered endocrine differentiation could in turn affect Neurog3
expression indirectly through non-Notch ligands (eg., some unknown
soluble molecules) or non-Notch receptor dependent pathways. It
would be of interest in the future to explore these latter possibilities.
In summary, our analysis revealed a previously unrecognized
impact of Neurog3 level on endocrine production. These ﬁndings
underscore the importance of understanding Neurog3 expression
control, including its expression pattern and its expression level in
individual cells, for both endocrine differentiation and diabetes
development for future studies.
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